Femasys (FEMY) Liabilities and Shareholders Equity (2020 - 2026)
Femasys (FEMY) posted Liabilities and Shareholders Equity of $16.5 million for Q1 2026, down 20.41% on a QoQ basis from $20.7 million in Q4 2025, and up 24.23% year-over-year from $13.3 million in Q1 2025.
Femasys (FEMY) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Femasys' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $16.5 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 24.23% year-over-year to $16.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.3 million (up 9.26% YoY) and the FY2025 annual result came in at $20.7 million, up 66.53% from the prior year.
- Liabilities and Shareholders Equity was $16.5 million for Q1 2026 at Femasys, down from $20.7 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $27.8 million in Q4 2023 and bottomed at $12.4 million in Q4 2024.
- A 5-year average of $18.2 million and a median of $16.5 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
- Peak annual rise in Liabilities and Shareholders Equity reached 75.74% in 2024, while the deepest fall reached 55.16% in 2024.
- Femasys' Liabilities and Shareholders Equity stood at $16.9 million in 2022, then surged by 64.28% to $27.8 million in 2023, then tumbled by 55.16% to $12.4 million in 2024, then jumped by 66.53% to $20.7 million in 2025, then fell by 20.41% to $16.5 million in 2026.
- Business Quant data shows FEMY's Liabilities and Shareholders Equity at $16.5 million in Q1 2026, $20.7 million in Q4 2025, and $16.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 31.62 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 20.88 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 50.83 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 39.01 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 8.78 Bn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 4.08 Bn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 12.48 Bn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 14.10 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 6.31 Bn |
| 10 | Femasys | 17.46 Mn | 12.07 Mn | - | 16.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.50 Mn |
| Dec 31, 2025 | 20.72 Mn |
| Sep 30, 2025 | 16.29 Mn |
| Jun 30, 2025 | 13.78 Mn |
| Mar 31, 2025 | 13.28 Mn |
| Dec 31, 2024 | 12.45 Mn |
| Sep 30, 2024 | 15.59 Mn |
| Jun 30, 2024 | 20.28 Mn |
| Mar 31, 2024 | 24.37 Mn |
| Dec 31, 2023 | 27.76 Mn |
| Sep 30, 2023 | 14.85 Mn |
| Jun 30, 2023 | 14.31 Mn |
| Mar 31, 2023 | 13.87 Mn |
| Dec 31, 2022 | 16.90 Mn |
| Sep 30, 2022 | 20.03 Mn |
| Jun 30, 2022 | 23.12 Mn |
| Mar 31, 2022 | 25.53 Mn |
| Dec 31, 2021 | 28.58 Mn |
| Sep 30, 2021 | 31.16 Mn |
| Jun 30, 2021 | 33.99 Mn |